FDA Advisory Panel To Discuss Vaccines Made From Human Tumor Cell Lines
This article was originally published in The Pink Sheet Daily
Executive Summary
The Sept. 19 meeting of FDA’s Vaccines and Related Biological Products Advisory Committee comes as several whole-cell cancer vaccines are in Phase III trials.
You may also be interested in...
Cancer Vaccines Headed For Mainstream
No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.
With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers
Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.